StockNews.com Begins Coverage on Curis (NASDAQ:CRIS)

Equities researchers at StockNews.com assumed coverage on shares of Curis (NASDAQ:CRIS) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their price objective on shares of Curis from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Monday, March 31st.

Curis Stock Performance

Shares of CRIS opened at $2.06 on Thursday. Curis has a 1 year low of $1.02 and a 1 year high of $16.93. The company’s 50 day simple moving average is $2.04 and its 200 day simple moving average is $3.13. The company has a market capitalization of $17.49 million, a price-to-earnings ratio of -0.26 and a beta of 3.65.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.14) by ($0.11). The business had revenue of $2.38 million for the quarter, compared to analyst estimates of $2.37 million. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%. During the same quarter last year, the business earned ($2.05) EPS. Equities analysts expect that Curis will post -7.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CRIS. Geode Capital Management LLC grew its position in Curis by 27.3% during the fourth quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock valued at $254,000 after acquiring an additional 17,820 shares during the period. Alyeska Investment Group L.P. acquired a new position in shares of Curis in the 4th quarter valued at about $607,000. Samsara BioCapital LLC purchased a new stake in shares of Curis during the 4th quarter worth about $607,000. M28 Capital Management LP increased its position in Curis by 23.5% during the 4th quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock worth $1,594,000 after purchasing an additional 99,108 shares in the last quarter. Finally, CM Management LLC increased its position in Curis by 83.3% during the 4th quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock worth $673,000 after purchasing an additional 100,000 shares in the last quarter. 29.97% of the stock is owned by hedge funds and other institutional investors.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.